Pfizer's Clostridioides Difficile Vaccine Fails To Prevent Infection

 

• Pfizer Inc 
  PFE -2.56%
   (Get Free Alerts for PFE) announced data from the CLOVER Phase 3 trial evaluating Clostridioides difficile vaccine candidate to prevent C. difficile infection (CDI).
• Initial analyses of two secondary endpoints indicated a highly favorable benefit in reducing CDI severity and 100% vaccine efficacy in preventing medically attended CDI.
• However, the trial did not meet its pre-specified primary endpoint of prevention of primary CDI. 
• Safety reviews indicated that the investigational vaccine was safe and well-tolerated.
• Vaccine efficacy under the primary endpoint was 31% following the third dose and 28.6% following the second dose for the C. difficile vaccine candidate. 
• For all CDI cases recorded 14 days post dose 3, vaccine efficacy 49%, 47%, and 31% up to 12 months, 24 months, and at the final analysis, respectively.
• Pfizer noted a highly favorable potential benefit in reducing the duration and severity of the disease. 
• None of the participants with CDI in the vaccine group required medical attention (including hospitalization) compared to 11 in the placebo group. 

https://www.benzinga.com/general/biotech/22/03/25905865/pfizers-clostridioides-difficile-vaccine-fails-to-prevent-c-difficile-infection